Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities
Cash runway extended beyond 2026
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.